The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic value of BRAF and KRAS mutations in colorectal cancer patients.
Paola Murata
No relevant relationships to disclose
Agostina Stradella
No relevant relationships to disclose
David Páez
No relevant relationships to disclose
Maria Tobeña
No relevant relationships to disclose
Ana Sebio
No relevant relationships to disclose
Laia Paré
No relevant relationships to disclose
Alan González
No relevant relationships to disclose
Iñigo Espinosa
No relevant relationships to disclose
Eduardo Targarona
No relevant relationships to disclose
Ignasi Gich
No relevant relationships to disclose
Agust Barnadas
No relevant relationships to disclose
Montserrat Baiget
No relevant relationships to disclose
Marta Martin-Richard
No relevant relationships to disclose